Heart Failure Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Heart failure (HF) is a clinical syndrome characterised by symptoms (dyspnoea, fatigue, orthopnoea, ankle oedema) and signs (elevated jugular venous pressure, pulmonary crackles, peripheral oedema) resulting from structural and/or functional cardiac abnormality that impairs the ability of the heart to fill or eject blood at a rate sufficient to meet metabolic demands. It is not a diagnosis in itself but a final common pathway of multiple cardiac diseases — predominantly coronary artery disease, hypertension, dilated cardiomyopathy, and valvular disease.

Heart failure is classified by left ventricular ejection fraction (LVEF) into three phenotypes, each with distinct epidemiology, pathophysiology, and treatment response:

• HFrEF (Heart Failure with Reduced EF): LVEF <40%. The best-characterised phenotype; has the most robust evidence base for pharmacological and device therapy. Driven predominantly by neurohormonal activation (RAAS, sympathetic nervous system), which is the mechanistic target of GDMT.
• HFmrEF (Heart Failure with Mildly Reduced EF): LVEF 40–49%. Previously termed 'mid-range'; emerging evidence suggests GDMT benefits similar to HFrEF, particularly with sacubitril-valsartan and SGLT2 inhibitors.
• HFpEF (Heart Failure with Preserved EF): LVEF ≥50%. Affects ~50% of all HF patients; predominantly affects older women with hypertension, obesity, diabetes, and AF. Historically lacked evidence-based therapy; SGLT2 inhibitors (EMPEROR-Preserved, DELIVER trials) now provide the first treatment with proven benefit.

Global prevalence of HF is approximately 64 million people (ESC Atlas 2021); 5-year mortality remains ~50% overall, similar to many common cancers, though modern GDMT has substantially improved outcomes in HFrEF. Heart failure is the leading cause of hospitalisation in adults aged over 65 in high-income countries.

Heart failure can result from virtually any cardiac disease. Identifying and treating the underlying cause is central to management:

Ischaemic Causes

Ischaemic cardiomyopathy — the most common cause of HFrEF in high-income countries, resulting from prior myocardial infarction(s) with resultant myocardial scarring, LV remodelling, and impaired systolic function. Coronary revascularisation (PCI or CABG) may recover hibernating myocardium and improve LVEF in selected patients (STICH trial: CABG + OMT reduces 10-year all-cause mortality vs OMT alone in ischaemic cardiomyopathy with LVEF ≤35%).

Non-Ischaemic Causes

• Dilated cardiomyopathy (DCM): Genetic (lamin A/C, titin, SCN5A, MYH7 mutations — ~30% of cases), idiopathic, inflammatory (myocarditis), toxin-induced (alcohol, doxorubicin, trastuzumab), peripartum, or tachycardia-mediated.
• Hypertensive cardiomyopathy: Chronic pressure overload leading to LVH, diastolic dysfunction, and eventually systolic failure. The most common substrate for HFpEF.
• Valvular cardiomyopathy: Chronic volume (AR, MR) or pressure (AS, MS) overload causing progressive LV dilatation or hypertrophy and eventual dysfunction.
• Inflammatory/infiltrative: Cardiac amyloidosis (AL type from plasma cell dyscrasias; ATTR type from transthyretin — wild-type in elderly men, hereditary in TTR mutation carriers), cardiac sarcoidosis, haemochromatosis, Fabry disease.

Acute Decompensated Heart Failure (ADHF)

ADHF presents as acute dyspnoea at rest, pulmonary oedema (cardiogenic), or cardiogenic shock. Precipitants include: non-compliance with medications or fluid restriction, uncontrolled hypertension, new AF or rapid AF, acute MI, severe infection, or anaemia. ADHF requires hospitalisation for IV diuresis (furosemide), haemodynamic optimisation, and precipitant reversal. In-hospital mortality for cardiogenic shock remains 30–50%.

Patient stratification in heart failure uses functional classification, objective haemodynamic measures, and comorbidity assessment to guide therapy escalation:

NYHA Functional Classification

• Class I: No limitation; ordinary physical activity does not cause symptoms. HF may be detected incidentally (reduced LVEF on imaging without symptoms = Stage B per ACC/AHA staging).
• Class II: Slight limitation; comfortable at rest but ordinary activity causes symptoms. First-line GDMT initiated at this stage for HFrEF.
• Class III: Marked limitation; comfortable at rest but minimal activity causes symptoms. Full GDMT with device therapy consideration (ICD, CRT).
• Class IV: Symptoms at rest; unable to perform any activity without discomfort. Advanced therapy evaluation (LVAD, transplant listing, palliative care).

Objective Measures for Treatment Eligibility

• Echocardiography: LVEF (primary eligibility criterion for GDMT and devices), LV dimensions, diastolic parameters (E/e' ratio, LA volume index, tricuspid regurgitation velocity for HFpEF diagnosis), RV function.
• BNP/NT-proBNP: Elevated natriuretic peptides confirm HF diagnosis and guide treatment titration. NT-proBNP >125 pg/mL (chronic HF) or >300 pg/mL (acute setting) supports HF diagnosis.
• Cardiopulmonary exercise test (CPET): Peak VO₂ <12 mL/kg/min suggests poor prognosis; <10 mL/kg/min is a key criterion for transplant listing.
• Haemodynamic assessment (right heart catheterisation): Required before transplant listing and LVAD implantation. Fixed pulmonary hypertension (PVR >5 Wood units unresponsive to vasodilators) is a contraindication to transplant.

Device Therapy Eligibility

• ICD (primary prevention): LVEF ≤35% on GDMT for ≥3 months; NYHA class II–III; expected survival >1 year with good functional status.
• CRT: LVEF ≤35%; LBBB with QRS duration ≥150 ms (Class I); or QRS 130–149 ms with LBBB (Class IIa). NYHA class II–III.

Heart failure management is built on guideline-directed medical therapy (GDMT), with device therapy and advanced interventions reserved for patients with progressive disease:

The Four Pillars of GDMT for HFrEF

• 1. ARNI (Angiotensin Receptor-Neprilysin Inhibitor) — Sacubitril-Valsartan (Entresto): Replaces ACE inhibitor or ARB as first-line RAAS blockade in HFrEF. PARADIGM-HF trial: 20% relative reduction in CV death or first HF hospitalisation vs enalapril (NNT ~32 over 27 months). Start at 49/51 mg BD; target 97/103 mg BD. Initiate at least 36 hours after last ACE inhibitor dose to avoid angioedema. If ARNI not tolerated or unavailable, use ACE inhibitor (ramipril, lisinopril) or ARB (valsartan, candesartan).
• 2. SGLT2 Inhibitors — Dapagliflozin (Farxiga) or Empagliflozin (Jardiance): The fourth pillar of GDMT since 2021. DAPA-HF trial (dapagliflozin): 26% relative reduction in the composite of worsening HF or CV death in HFrEF (NNT ~21 over 18 months), benefit independent of diabetes status. EMPEROR-Reduced trial (empagliflozin): similar outcomes. EMPEROR-Preserved and DELIVER trials established benefit in HFpEF. Dose: dapagliflozin 10 mg OD; empagliflozin 10 mg OD.
• 3. Beta-Blockers: Three agents proven to reduce mortality in HFrEF — bisoprolol (CIBIS-II: 34% relative mortality reduction), carvedilol (COPERNICUS: 35% reduction in severe HF), metoprolol succinate CR/XL (MERIT-HF: 34% reduction). Initiated at low dose when patient is euvolaemic and uptitrated to target dose. Not initiated during acute decompensation.
• 4. Mineralocorticoid Receptor Antagonists (MRA) — Eplerenone or Spironolactone: RALES trial (spironolactone): 30% mortality reduction in NYHA class III–IV HFrEF. EMPHASIS-HF (eplerenone): 37% reduction in CV death or HF hospitalisation in NYHA class II. Monitor for hyperkalaemia and renal impairment at 1–2 weeks, 4 weeks, and 3 months after initiation.

Diuretics

Loop diuretics (furosemide, torasemide, bumetanide) are the cornerstone of decongestion in acute and chronic HF. Target: euvolaemia (absence of oedema, JVP <8 cm, clear lung bases). Torasemide has superior bioavailability and may reduce HF hospitalisation compared to furosemide (TRANSFORM-HF trial results inconclusive but torasemide preferred in diuretic resistance). Thiazide-type diuretics (hydrochlorothiazide, metolazone) added for diuretic resistance ('sequential nephron blockade').

Device Therapy

• ICD (Implantable Cardioverter-Defibrillator): SCD-HeFT trial: ICD reduces all-cause mortality by 23% vs placebo in NYHA II–III with LVEF ≤35%. CRT-D combines resynchronisation with defibrillation for eligible patients.
• CRT (Cardiac Resynchronisation Therapy): CARE-HF and COMPANION trials demonstrate 36% reduction in HF hospitalisation or death. Most benefit in LBBB with QRS ≥150 ms. CRT may improve LVEF by 10–15% absolute with reverse remodelling. CRT-D vs CRT-P: CRT-D preferred in patients who also meet ICD criteria.

Advanced Therapies

• LVAD (Left Ventricular Assist Device): HeartMate 3 (centrifugal-flow) — MOMENTUM 3 trial: 79% survival free of disabling stroke or device reoperation at 2 years. Used as bridge-to-transplant (BTT), bridge-to-candidacy, or destination therapy (DT) for transplant-ineligible patients.
• Heart transplantation: Gold standard for end-stage HF; discussed separately.
• Ivabradine: Added to GDMT when sinus rhythm with HR ≥70 bpm despite target dose beta-blocker; SHIFT trial: 18% reduction in CV death or HF hospitalisation.

Contemporary GDMT for HFrEF has transformed the natural history of heart failure, with combined pharmacological therapy offering substantial mortality and hospitalisation benefits:

GDMT Mortality and Hospitalisation Reduction

A pivotal 2020 modelling study (Vaduganathan, JACC) estimated that simultaneous initiation of all four GDMT pillars (ARNI, beta-blocker, MRA, SGLT2 inhibitor) in HFrEF patients reduces the risk of cardiovascular death or first HF hospitalisation by approximately 62% compared to placebo, with an estimated gain of 6.3 years free from cardiovascular death or HF hospitalisation for a 55-year-old with HFrEF. Each pillar contributes independently:

• ARNI (sacubitril-valsartan): ~20% relative risk reduction in CV death/HF hospitalisation vs enalapril (PARADIGM-HF)
• Beta-blocker (bisoprolol/carvedilol/metoprolol succinate): ~34% relative mortality reduction (pooled RCTs)
• MRA (spironolactone/eplerenone): ~30% relative mortality reduction (RALES) to ~37% CV death/HF hospitalisation reduction (EMPHASIS-HF)
• SGLT2 inhibitor: ~25–26% relative risk reduction in worsening HF or CV death (DAPA-HF, EMPEROR-Reduced)

Device Therapy Benefits

ICD for primary SCD prevention reduces all-cause mortality by ~23% over 5 years in HFrEF (SCD-HeFT; NNT ~14 over 5 years). CRT reduces HF hospitalisation by ~36% and all-cause mortality by ~24% in appropriately selected patients (CARE-HF). CRT induces reverse LV remodelling, improving LVEF by 10–15% absolute in responders (~70% of cases).

Quality of Life Improvements

GDMT substantially improves NYHA functional class, exercise tolerance (6MWT, peak VO₂), and health-related quality of life (Kansas City Cardiomyopathy Questionnaire — KCCQ scores). LVAD support in end-stage HF improves NYHA class from IV to II in the majority of patients, restoring meaningful functional independence. Heart transplantation restores near-normal quality of life and exercise capacity in properly selected recipients.

GDMT requires careful monitoring for treatment-related adverse effects, particularly during initiation and uptitration:

ARNI (Sacubitril-Valsartan) Risks

• Symptomatic hypotension: Most common adverse effect; systolic BP <95 mmHg in ~14% of patients. Manage by reducing concomitant diuretic dose, splitting doses, or reducing ARNI dose.
• Angioedema: Rare but serious (0.4–0.5%); rate higher in patients switched from ACE inhibitors (mandatory 36-hour washout required). Black patients have higher baseline risk.
• Renal impairment: Rise in serum creatinine of <30% from baseline is acceptable; >30% rise warrants dose reduction.
• Hyperkalaemia: K >5.5 mmol/L — reduce or hold MRA; K >6.0 mmol/L — hold ARNI and MRA, add potassium binders (patiromer, sodium zirconium cyclosilicate).

SGLT2 Inhibitor Risks

• Urinary and genital mycotic infections — managed with hygiene and topical antifungal therapy.
• Urinary frequency and polyuria — usually mild and transient.
• Volume depletion with excessive diuresis — reduce loop diuretic dose by 20–50% when initiating SGLT2 inhibitor in euvolaemic patients.
• Euglycaemic diabetic ketoacidosis (EDKA) — rare; more common in type 1 diabetes or severe caloric restriction. Hold SGLT2 inhibitor 3 days before major surgery.
• Lower limb amputations (canagliflozin-specific signal): not seen with dapagliflozin or empagliflozin in HF trials.

Beta-Blocker Risks

• Symptomatic bradycardia and AV block (more common with bisoprolol in AF with slow ventricular rate).
• Symptomatic hypotension — manage by reducing diuretics first.
• Worsening of COPD/asthma (beta-1 selective agents — bisoprolol, metoprolol succinate — preferred in mild-moderate obstructive airway disease).
• Fatigue and sexual dysfunction — often transient; uptitrate slowly.

MRA Risks

• Hyperkalaemia — the primary concern; avoid if serum K >5.0 mmol/L or eGFR <30 mL/min at initiation. Check renal function and electrolytes at 1 week, 4 weeks, and 3 months.
• Gynaecomastia (spironolactone): up to 10% in men; switch to eplerenone if problematic.

Device Therapy Risks

• ICD: Inappropriate shocks (5–10% per year) from AF/SVT — minimised with programming optimisation and antiarrhythmic therapy. Lead failure, infection (1–2%), subcutaneous haematoma.
• LVAD: Major bleeding (20–30% per year; primarily GI tract), stroke (15–20% over 2 years), device infection (10–15% per year), pump thrombosis (<1% per year with HeartMate 3).

Heart failure management requires structured, proactive follow-up to maintain stability, optimise GDMT doses, detect decompensation early, and reassess advanced therapy eligibility:

Pharmacotherapy Monitoring

• GDMT initiation: All four pillars should be started simultaneously at low doses and uptitrated at 2-week intervals when clinically feasible, as recommended by ESC 2021 and ACC/AHA 2022. Uptitration to target (or maximally tolerated) doses is the primary goal — partial doses provide proportionally less benefit.
• Renal function and electrolytes: Check at 1–2 weeks after any GDMT change, at 4 weeks, and then every 3–6 months in stable patients. Target eGFR >30 mL/min and K <5.0 mmol/L for full GDMT.
• Natriuretic peptides (BNP/NT-proBNP): Monitor response to therapy; a >30% reduction in NT-proBNP from baseline after 3–6 months of GDMT correlates with improved outcomes. Persistently elevated values suggest residual congestion or subtherapeutic GDMT.

Echocardiographic Follow-Up

• Repeat echocardiography 3–6 months after GDMT initiation or dose optimisation to assess LVEF trajectory. Improvement in LVEF to >40% (HFrecovery or HFimproved) occurs in 30–40% of new HFrEF patients and may allow cautious GDMT dose reduction after sustained remission (>2 years); do not discontinue GDMT without specialist guidance.
• Reassess ICD/CRT eligibility if LVEF remains ≤35% after ≥3 months of optimised GDMT.

Decongestion Monitoring

• Daily weight monitoring (alert if weight gain >2 kg over 2–3 days — indicative of fluid retention).
• Salt restriction (<2 g/day sodium) and fluid restriction (1.5–2 L/day) in symptomatic patients.
• Remote haemodynamic monitoring: CardioMEMS (pulmonary artery pressure monitoring) reduces HF hospitalisation by 37% in NYHA class III patients (CHAMPION trial).

Advanced Therapy Reassessment

• INTERMACS profiles 1–3 (rapidly deteriorating on IV inotropes, advanced haemodynamic compromise): urgent LVAD evaluation and transplant listing reassessment.
• Palliative care integration: introduced at diagnosis and actively reassessed at each NYHA IV episode, LVAD implantation, and transplant listing.

Heart failure imposes enormous economic burden — estimated at USD $108 billion globally per year (2012 data; substantially higher in 2026). Costs span hospitalisation, pharmacotherapy, devices, and long-term support:

Pharmacotherapy Costs

• Sacubitril-valsartan (Entresto): USA: ~USD $600–$700/month without insurance. India: INR 3,500–8,000/month depending on dose. UK (NHS): fully funded on prescription. Generic sacubitril-valsartan now available in several countries, substantially reducing cost.
• SGLT2 inhibitors (dapagliflozin/empagliflozin): USA: ~USD $400–$500/month without insurance. India: INR 2,000–4,000/month. EU: EUR €60–€120/month with insurance.
• Generic GDMT (bisoprolol, spironolactone, ramipril): Very low cost globally (USD $5–$20/month combined); major barrier to access in LMIC is awareness and prescriber practice, not cost.

Device Therapy Costs

• ICD implantation: USA: USD $30,000–$75,000 (procedure + device). India: USD $10,000–$25,000. Germany: EUR €25,000–€50,000 (covered by GKV). Thailand: USD $20,000–$40,000.
• CRT-D implantation: USA: USD $50,000–$120,000. India: USD $15,000–$35,000. Turkey: USD $15,000–$30,000.
• LVAD (HeartMate 3): USA: USD $150,000–$300,000 (device + implant + 1 year follow-up). India: USD $80,000–$120,000 at select centres. Limited availability in LMIC settings.

Hospitalisation Costs

• Acute decompensated HF hospitalisation: USA: average USD $12,000–$25,000 per admission. India: USD $800–$3,000. Germany: EUR €6,000–€15,000.
• 30-day readmission rates of 20–25% in HF substantially amplify total costs. Remote monitoring programmes reduce readmissions and are cost-effective (CardioMEMS: USD $20,000/year hardware, but reduces hospitalisation costs by ~USD $15,000/year in high-risk NYHA III patients).

For patients with persistent or end-stage heart failure despite full GDMT and device therapy, the following advanced alternatives are available:

Heart Transplantation

Orthotopic heart transplantation remains the gold standard for end-stage HF. Median post-transplant survival is approximately 12–13 years (ISHLT 2022 Registry), with a 1-year survival of ~85% and 5-year survival of ~75–80%. Eligibility requires NYHA class IIIb–IV symptoms refractory to GDMT, peak VO₂ <12 mL/kg/min (or <50% predicted), lack of absolute contraindications (active malignancy, fixed PVR >5 Wood units, severe irreversible non-cardiac organ failure, active substance abuse), and psychosocial suitability. Limited by global donor availability (~6,000–7,000 transplants per year worldwide).

LVAD as Destination Therapy

For transplant-ineligible patients with end-stage HFrEF, destination therapy (DT) LVAD provides meaningful survival advantage over continued medical therapy. ROADMAP trial demonstrated LVAD DT improved survival and quality of life vs OMT in ambulatory NYHA class IV patients. HeartMate 3 has substantially improved the risk-benefit profile with dramatically reduced pump thrombosis. Major ongoing challenges include GI bleeding, stroke, and infection during long-term LVAD support.

Management of HFpEF — Emerging Evidence

HFpEF historically lacked disease-modifying therapy. SGLT2 inhibitors (empagliflozin in EMPEROR-Preserved: 21% relative reduction in HF hospitalisation; dapagliflozin in DELIVER: 18% relative reduction in worsening HF or CV death) are now the first proven treatments for HFpEF. Aggressive management of comorbidities — hypertension (target <130/80 mmHg), AF (rhythm or rate control), obesity, and diabetes — remains central. Finerenone (nMRA) is under investigation in HFpEF with diabetes. Tirzepatide (GLP-1/GIP dual agonist) demonstrated significant symptom improvement in HFpEF with obesity (SUMMIT trial).

Palliative Care Integration

Palliative care should be introduced early in the HF journey and integrated in parallel with disease-modifying therapy rather than reserved for the terminal phase. Symptom management with optimised diuretics, low-dose opioids for refractory dyspnoea, anxiolytics, and psychological support significantly improves quality of life. Advance care planning discussions — including ICD deactivation, preferences regarding hospitalisation, and end-of-life care goals — should be conducted while the patient has decision-making capacity.